<DOC>
	<DOCNO>NCT00005993</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Filgrastim stem cell factor may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect cancer therapy . Peripheral stem cell transplantation may able replace immune cell destroy therapy use kill cancer cell . PURPOSE : Phase I trial study effectiveness interleukin-2 stem cell factor follow peripheral stem cell transplantation treat patient non-Hodgkin 's lymphoma , Hodgkin 's disease , advance breast cancer .</brief_summary>
	<brief_title>Biological Therapies Following Peripheral Stem Cell Transplantation Treating Patients With Non-Hodgkin 's Lymphoma , Hodgkin 's Disease , Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety maximum tolerate dose interleukin-2 ( IL-2 ) stem cell factor ( SCF ) follow autologous peripheral blood stem cell transplantation patient non-Hodgkin 's lymphoma advance breast cancer . II . Determine effectiveness filgrastim ( G-CSF ) SCF mobilize agent patient . OUTLINE : This dose escalation study stem cell factor ( SCF ) . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) follow SCF SC daily 7-10 day . Beginning fifth day G-CSF SCF injection , peripheral blood stem cell ( PBSC ) collect several day . PBSC later reinfused patient receive G-CSF SC daily hematopoietic recovery . At least 30 day later 110 day follow transplant , patient experience adverse reaction SCF mobilization begin posttransplant immunotherapy . Patients receive interleukin-2 SC daily SCF SC 3 time weekly 6 week . Treatment continue absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos SCF posttransplant immunotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow 1 week , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A maximum 27 patient accrue study within 1-1.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Hodgkin 's disease , nonHodgkin 's lymphoma , advanced stage breast cancer Planned treatment autologous peripheral blood stem cell transplantation No Tcell lymphomas Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 65 Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Immunologic : No history seasonal recurrent asthma within past 5 year No concurrent asthmatic symptom ( e.g. , wheeze ) relate current respiratory tract infection No anaphylactic/anaphylactoid type event manifest disseminated urticaria , laryngeal edema , hypotension , and/or bronchospasm ( e.g. , food insect venom ) within past 5 year Drug allergy manifest solely rash allow No history angioedema recurrent urticaria lasting longer 14 day No history hereditary acquire angioedema No known allergy E. coli derive product Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 1 week since prior hematopoietic growth factor Chemotherapy : Not specify Endocrine therapy : No concurrent steroids Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent beta adrenergic block agent No concurrent therapeutic antibiotic posttransplant No concurrent IV hyperalimentation IV fluid posttransplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>